Chronological evaluation of liver enhancement in patients with chronic liver disease at Gd-EOB-DTPA-enhanced 3-T MR imaging: Does liver function correlate with enhancement?

Japanese Journal of Radiology

Volumn 30, Issue 1, 2012, Pages 25-33

  Nakamura, Shinichi ^a   Awai, Kazuo ^b   Utsunomiya, Daisuke ^a   Namimoto, Tomohiro ^a   Nakaura, Takeshi ^c   Morita, Kosuke ^d   Yamashita, Yasuyuki ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c Amakusa Regional Medical Center   (Japan)

^d KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Chronic liver disease; Gd EOB DTPA; Hepatobiliary phase; Scan window; Signal intensity

Indexed keywords

ALBUMIN; GADOXETIC ACID; CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM PENTETATE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CHRONIC LIVER DISEASE; FEMALE; HUMAN; IMAGE ENHANCEMENT; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTHROMBIN TIME; CHRONIC DISEASE; LIVER; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TUMOR; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; STATISTICS; THREE DIMENSIONAL IMAGING; TIME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; IMAGING, THREE-DIMENSIONAL; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84862308603     PISSN: 18671071     EISSN: 1867108X     Source Type: Journal    
DOI: 10.1007/s11604-011-0003-1     Document Type: Article

References (31)

1. Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV. Hepa-tobiliary- specific MR contrast agents: role in imaging the liver and biliary tree. Radio Graphics. 2009;29:1725-48.
2. Bang DH, Park SH, Jun HY, Moon HB, Kim SU, Yu DY, et al. Gd-EOB-DTPA enhanced micro-MR imaging of hepatic tumors in H-ras 12V transgenic mice. Acad Radiol. 2011;18:13-9.
3. Hamm B, Staks T, Muhler A, Bollow M, Taupitz M, Frenzel T, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepa-tobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology. 1995;195:785-92.
4. Bluemke DA, Sahani D, Amendola M, Balzer T, Breuer J, Brown JJ, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: US multicenter phase III study. Radiology. 2005;237:89-98. (Pubitemid 41346150)
5. Hammerstingl R, Huppertz A, Breuer J, Balzer T, Blakeborough A, Carter R, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strat-egy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol. 2008;18:457-67. (Pubitemid 351248177)
6. Vogl TJ, Kummel S, Hammerstingl R, Schellenbeck M, Schum-acher G, Balzer T, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology. 1996;200:59-67. (Pubitemid 26197732)
7. Zech CJ, Herrmann KA, Reiser MF, Schoenberg SO. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci. 2007;6:43-52.
8. Jung G, Breuer J, Poll LW, Koch JA, Balzer T, Chang S, et al. Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. Acta Radiol. 2006;47:15-23. (Pubitemid 43177525)
9. Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO. Diagnostic performance and description of morphological fea-tures of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol. 2008;43:504-11.
10. Motosugi U, Ichikawa T, Tominaga L, Sou H, Sano K, Ichikawa S, et al. Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time? Eur Radiol. 2009;19:2623-9.
11. Motosugi U, Ichikawa T, Sou H, Sano K, Tominaga L, Kitamura T, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which bio-logical markers of the liver function affect the enhancement? J Magn Reson Imaging. 2009;30:1042-6.
12. Ryeom HK, Kim SH, Kim JY, Kim HJ, Lee JM, Chang YM, et al. Quantitative evaluation of liver function with MRI using Gd-EOB-DTPA. Korean J Radiol. 2004;5:231-9.
13. Tschirch FT, Struwe A, Petrowsky H, Kakales I, Marincek B, Weishaupt D. Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol. 2008;18:1577-86.
14. Brody JM, Schafer L, Tung GA, Breuer J, Shamsi K. Conspicuity of liver hemangiomas: short tau inversion recovery, T1, and T2 imaging with gadolinium ethoxybenzyl diethylenetriamine-pentaacetic acid. J Magn Reson Imaging. 2005;21:391-7. (Pubitemid 40446434)
15. Saito K, Kotake F, Ito N, Ozuki T, Mikami R, Abe K, et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci. 2005;4:1-9.
16. Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008;247:311-30.
17. Choi SH, Lee JM, Yu NC, Suh KS, Jang JJ, Kim SH, et al. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI. AJR Am J Roentgenol. 2008;191:529-36.
18. Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol. 2006;101: 513-23. (Pubitemid 43340927)
19. Huppertz A, Balzer T, Blakeborough A, Breuer J, Giovagnoni A, Heinz-Peer G, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison ofgadoxetic acid-enhanced MR images with intraoperative findings. Radiology. 2004;230: 266-75. (Pubitemid 37549812)
20. Kim YK, Kim CS, Han YM, Park G. Detection of small hepa-tocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglu-mine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging? Invest Radiol. 2010;45:740-6.
21. Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB. Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. Radio Graphics. 2008; 28:747-69.
22. Kim T, Murakami T, Hasuike Y, Gotoh M, Kato N, Takahashi M, et al. Experimental hepatic dysfunction: evaluation by MRI with Gd-EOB-DTPA. J Magn Reson Imaging. 1997;7:683-8. (Pubitemid 28365618)
23. Katsube T, Okada M, Kumano S, Hori M, Imaoka I, Ishii K, et al. Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest Radiol. 2011;46:277-83.
24. Katsube T, Okada M, Kumano S, Imaoka I, Kagawa Y, Hori M, et al. Estimation of liver function using T2* mapping on gado-linium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging. Eur J Radiol 2011 [Epub ahead of print].
25. Mori H, Furuya K, Akimoto S, Ajioka R, Emoto T. Examination of the means of measuring liver function in the hepatobiliary phase. Nippon Hoshasen Gijutsu Gakkai Zasshi. 2009;65: 1502-11.
26. Nilsson H, Nordell A, Vargas R, Douglas L, Jonas E, Blomqvist L. Assessment of hepatic extraction fraction and input relative blood flow using dynamic hepatocyte-specific contrast-enhanced MRI. J Magn Reson Imaging. 2009;29:1323-31.
27. Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, Vogler H, Frenzel T, Gries H. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Re-son Med. 1991;22:233-7. discussion 42.
28. Pascolo L, Cupelli F, Anelli PL, Lorusso V, Visigalli M, Uggeri F, et al. Molecular mechanisms for the hepatic uptake of mag-netic resonance imaging contrast agents. Biochem Biophys Res Commun. 1999;257:746-52. (Pubitemid 29301512)
29. van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion trans-porting polypeptide Oatp1. J Pharmacol Exp Ther. 1999;290: 153-7. (Pubitemid 29302315)
30. Bollow M, Taupitz M, Hamm B, Staks T, Wolf KJ, Weinmann HJ. Gadolinium-ethoxybenzyl-DTPA as a hepatobiliary contrast agent for use in MR cholangiography: results of an in vivo phase-I clinical evaluation. Eur Radiol. 1997;7:126-32. (Pubitemid 127538537)
31. Balzan S, Belghiti J, Farges O, Ogata S, Sauvanet A, Delefosse D, et al. The "50-50 criteria" on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg. 2005;242:824-8. discussion 8-9.